3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
6
Lymphoid
6
Other hematologic neoplasm
2
CNS
2
Conditions
Glioma
5
Diffuse Intrinsic Pontine Glioma
4
Recurrence
2
Glioblastoma
2
Brain Neoplasms
2
Rhabdoid Tumor
1
Oligodendroglioma
1
Neoplasms
1
Meningioma
1
Gliosarcoma
1
Astrocytoma
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Drug Therapy
3
Antilymphocyte Serum
3
verubulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
Panobinostat
×
CNS
×
Clear all
NCT04341311
2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1
Terminated
4 enrolled
NCT01115036
2013-06-19
CLBH589C
Duke University
Phase 2
Withdrawn